Abstract：ObjectiveTo investigate the clinicopathological features,differential diagnosis and prognosis of diffuse large B cell lymphoma of the breast(PBDLBCL).Methods9 cases of patients with diffuse large B cell lymphoma of breast treated in our hospital from March 2013 to August 2017 were selected,and the clinicopathological features and immunophenotype were analyzed retrospectively.The literatures were reviewed.Results9 cases of diffuse large B cell lymphoma of the breast were female,aged 22-80 years,median age of 52 years.5 cases were right,3 cases were left and 1 cases were bilateral.8 cases were diagnosed as primary and 1 were secondary.Immunophenotype:9 cases of diffuse large B cell lymphoma of breast were positive expression of LCA,CD20 and CD79a,CD3,CD5 and CK were negative,Ki-67 index was 70%-95%,median 90%.ConclusionBreast lymphoma is rare,and most of the patients are female.It is very common in unilateral mammary gland.The main pathological type is diffuse large B cell type.Pathological,light and immunohistochemical findings are helpful in the diagnosis and differential diagnosis.
涂剑宏 ;瞿伟. 乳腺弥漫大B细胞淋巴瘤9例临床病理特征分析[J]. 中国当代医药, 2018, 25(6): 102-104.
TU Jian-hong ;QU Wei. Clinicopathological features of diffuse large B cell lymphoma of the breast for a report of 9 cases. 中国当代医药, 2018, 25(6): 102-104.
Swerdlow SH，Campo E，Harris NL，et al.World Health Organizationclassificationoftumoursofhaematopoieticandlymphoid tissues[M].4thedition.Lyon：LARC Press，2008：338-346.
[2]
Colomo L，Lopez-Guillermo A，Perales M，et al.Clinical impact of the differentiation profile asseaed by immunophenotyping in patients with diffuse large B-cell lymphoma[J].Blood，2003，101（1）：78-84.
Yhim HY，Kang HJ，Choi YH，et al.Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma；Consortium for Improving Survival of Lymphoma（CISL） study[J].BMC Cancer，2010，22（10）：321.
[6]
Jung SP，Han KM，Kim SJ，et al.Primary follicular lymphoma in a male breast：a case report[J].Cancer Res Treat，2014，46（1）：104-107.
[7]
Hosein PJ，Maragulia JC，Salzberg MP，et al.A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era[J].Br J Haematol，2014，165（3）：358-363.
[8]
Surov A，Holzhausen HJ，Wienke A，et al.Primary and secondary breast lymphoma：prevalence，clinical signs and radiological features[J].Br Radiol，2012，85（1014）：e195-e205.
[9]
Cheah CY，Campbell BA，Seymour JF.Primary breast lymphoma[J].Cancer Treat Rev，2014，40（8）：900-908.
[10]
Rooney N，Snead D，Goodman S，et al.Primary breast lymphoma with akin involvement arising in lymphocytic lobulitis[J].Histopathology，1994，24（1）：81-84.
[11]
Teras IR，Patel AV，Hildebrand JS，et al.Posunenopausal unopposed estrogen and estrogen plus progestin use and risk of non-Hodgkin lymphoma in the An]efiean Cancer Society Cancer Prevention Study-1I Cohoa[J].Leuk Lynrphoma，2013，54（4）：720-725.
[12]
Ganjoo K，Advani R，Mariappan MR，et al.Non-Hodgkin lymphoma of the breast[J].Cancer，2007，110（1）：25-30.
Ryan G，Martinelli G，Kuper-Hommel M，et al.Primary diffuse large B-cell lymphoma of the breast：prognostic factors and outcomes of a study by the lnternational Extranodal Lymphoma Study Group[J].Ann Oncol，2008，19（2）：233-241.
[15]
Radkani P，Joshi D，Paramo JC，et al.Primary breast lymphoma：30 years of experience with diagnosis and treatment at a single medical center[J].JAMA Surg，2014，32（2）：114-120.
京公网安备 11010502046607号